Introducing the new AltIndexLearn more
Karyopharm Therapeutics

Karyopharm Therapeutics (KPTI) Earnings Prediction

Updated August 11, 2026 · AltIndex alt-data view going into the print

AltIndex AI Score on Karyopharm Therapeutics is 48 — signals are mixed heading into the print. Underlying trend: 2 of 5 tracked signals trending down over the last 3 months.

Next report
Sunday, August 9, 2026
EPS Estimate
$-2.26
AltIndex AI Score
48
AI Prediction
Mixed signals

KPTI stock price — last 3 months

Karyopharm Therapeutics (KPTI) is trading at $1.96, down 77.9% over the last 3 months (from $8.85 three months ago).

What the alt-data signals say about Karyopharm Therapeutics right now

Trends across the last 3 months — the run-up to Karyopharm Therapeutics’s next earnings print.

Signal Current 3-month change
Job postings 11 ↓ -35.3%
LinkedIn headcount 320 → +2.2%
Web traffic 9,874 ↓ -6.9%
Employee business outlook 62% Neutral → flat
X followers 1,561 → +0.3%

Full daily-resolution trend charts on every signal are on the KPTI ticker page.

Get alerted when KPTI signals inflect

AltIndex stock alerts fire when alt-data on KPTI breaks out — web traffic spike, hiring surge, sentiment shift — often days before the earnings number confirms it.

Sign up to AltIndex →

Karyopharm Therapeutics earnings: frequently asked questions

When does Karyopharm Therapeutics report earnings next?
Karyopharm Therapeutics (KPTI) is scheduled to report next earnings on Sunday, August 9, 2026. The exact pre-market or post-market time is set by the company a few days ahead; see the official investor-relations page for confirmation.
What does the AltIndex AI Score say about Karyopharm Therapeutics going into earnings?
Current AI Score on Karyopharm Therapeutics: 48 — Mixed signals. The AI Score combines 10,000+ alternative-data and financial signals into one 0–100 number; higher = signals lean bullish, lower = signals lean bearish. Full per-signal breakdown is on the KPTI ticker page.
What is the EPS estimate for Karyopharm Therapeutics?
Analyst consensus EPS estimate for Karyopharm Therapeutics’s next quarter: $-2.26. We refresh this from analyst-estimate data daily.
How accurate are AltIndex’s earnings predictions for Karyopharm Therapeutics?
AltIndex doesn’t predict the exact EPS number — the alt-data signals don’t see the financials. What the signals can do is tell you whether the underlying business momentum (web traffic, hiring, social audience, sentiment) supports the analyst consensus or contradicts it. AltIndex publishes the full pick history at altindex.com/results — including the misses — so you can verify how the signal-driven calls have performed.
Where can I see the full signal breakdown on Karyopharm Therapeutics?
Visit https://altindex.com/ticker/kpti for the complete per-signal view: AI Score history, web traffic trend chart, 8-platform social audience tracking, hiring activity, news mention volume, sentiment scoring, insider trades and Congressional disclosures.
How can I get alerted before Karyopharm Therapeutics reports earnings?
AltIndex stock alerts fire when alt-data signals on a stock break out of their historical range — often days or weeks before the earnings number confirms it. Add KPTI to your watchlist and you’ll get notified when its signals shift. See altindex.com/stock-alerts for the full alert categories.

Other earnings predictions

Other companies in the AltIndex universe reporting earnings in the next 2 weeks, sorted by AI Score.

← Back to the full earnings calendar

See every alt-data signal on KPTI

Sign up to see the full daily-resolution trend charts on every signal AltIndex tracks for Karyopharm Therapeutics — web traffic, hiring, 8-platform social audience, sentiment, insider trades and the full AI Score breakdown.

Sign up to AltIndex → Log in
About AltIndex

Smarter investing with alternative data analytics and AI-powered insights.

Download on the App Store Get it on Google Play
Newsletter

AI stock picks and market insights, straight to your inbox.

Company
Features
More Data
© 2026 AltIndex. All rights reserved.